Novo Nordisk Sues Clinics for Allegedly Selling Cheaper, Unauthorized Versions of Ozempic and Wegovy

Novo Nordisk on Tuesday sued five medical spas and wellness clinics for allegedly selling cheaper, unauthorized versions of the company’s weight loss drugs Ozempic and Wegovy.

The Danish drugmaker initiated the lawsuits in federal courts in New York, Texas, Florida and Tennessee, according to complaints obtained by CNBC.

The suits accused the spas and clinics of marketing and selling “compounded” drug products that claim to contain semaglutide, the active ingredient in both Ozempic and Wegovy. Compounded drugs are custom-made versions of a treatment that are not approved by the Food and Drug Administration.

Read the source article at cnbc.com